Table 2.
Multispecific T cell engagers in early stage clinical trials (initiating 2019–2023), as of July 2023
| Drug name | Format | Specificity | Indication | Clinical trial | Phase | Sponsor |
|---|---|---|---|---|---|---|
| Plamotamab (XmAb13676) | XmAb Fab-Fc-scFv | CD20/CD3 | NHL, CLL | NCT02924402 | 1 | Xencor |
| GB261 | Hz IgG1-based | CD20/CD3 | NHL, CLL | NCT04923048 | 1/2 | Genor Biopharma |
| CM355 | NA | CD20/CD3 | NHL | NCT05210868 | 1/2 | Beijing InnoCare |
| JS203 | NA | CD20/CD3 | NHL | NCT05618327 | 1 | Shanghai Junshi Bioscience |
| IGM-2323 (imvotamab) | IgM-based 10 + 1 | CD20/CD3 | NHL | NCT04082936 | 1/2 | IGM Biosciences |
| TQB2934 | IgG1-based | BCMA/CD3 | MM | NCT05646758 | 1 | Chia Tai Tianqing Pharma |
| Abbv-383 (TNB-383B) | Hu IgG4-based | BCMA/CD3 | MM | NCT03933735 | 1/2 | AbbVie |
| Alnuctamab (CC-93269) | Hz 2 + 1VH−VL± CrossMab | BCMA/CD3 | MM | NCT03486067 | 1 | Celgene (BMS) |
| REGN5459 | mAb human VelociBi | BCMA/CD3 | MM | NCT04083534 | 1/2 | Regeneron |
| EMB-06 | 2 + 2 CrossMab FIT-Ig | BCMA/CD3 | MM | NCT04735575 | 1/2 | EpimAb Shangai |
| Forimtamig (RG6324) | Hz 2 + 1VH-VL ± CrossMab | GPRC5D/CD3 | MM | NCT04557150 | 1 | Roche |
| RO7443904, RG6333 | 1 + 1 IgG1-based | CD19/CD28 | NHL | NCT05219513 | 1 | Roche |
| Englumafusp α (RO7227166, RG6076) | 4-1BBL-anti- CD19 IgG1 fusion | CD19/CD137 | NHL | NCT04077723 | 1 | Roche |
| GNR-084 | BiMS format | CD19/CD3 | B-ALL | NCT04601584 | 1/2 | GENERIUM |
| TNB-486 | Hu IgG4-based | CD19/CD3 | NHL | NCT04594642 | 1 | TeneoTwo |
| CLN-049 | Hz IgG1-like (+ 2 scFv), homodimer | FLT3/CD3 | AML, MS | NCT05143996 | 1 | Cullinan Oncology |
| MGD024 | DART-Fc | CD123/CD3 | AML | NCT05362773 | 1 | MacroGenics |
| APVO436 | ADAPTIR | CD123/CD3 | AML, MDS | NCT03647800 | 1 | Aptevo |
| IGM-2644 | IgM-based 10 + 1 | CD38/CD3 | MM | NCT05908396 | 1 | IGM Biosciences |
| ISB 1342 | BEAT 1.0 | CD38/CD3 | MM | NCT03309111 | 1 | Ichnos Sciences |
| Y150 | YBODY (scFv-Fab-Fc) | CD38/CD3 | MM | NCT05011097 | 1 | Wuhan YZY Biopharma |
| XmAb18968 | Bispecific Fc domains | CD38/CD3 | AML, T-ALL, T-LBL | NCT05038644 | 1 | IST |
| SLAMF7 BATs | Chemically Hetero-conjugated | SLAMF7/CD3 | MM | NCT04864522 | 1 | University of Virginia |
| Cevostamab (RG6160, BFCR4350A) | 1 + 1 CrossMab | FCRH5/CD3 | MM | NCT03275103 | 1 | Genentech/Roche |
| NCT05535244 | 1/2 | |||||
| JNJ-75348780 | NA | CD22/CD3 | NHL, CLL | NCT04540796 | 1 | Janssen |
| ATG-101 | NA | PD-L1/CD137 | NHL | NCT04986865 | 1 | Antengene |
| ONO-4685 | NA | PD-1/CD3 | T cell lymphoma | NCT05079282 | 1/2 | Ono Pharmaceutical |
| NVG-111 | Tandem scFv | ROR1/CD3 | CLL, MCL | NCT04763083 | 1 | NovalGen |
| SAR442257 | CODV-Fab | CD38/CD3/CD28 | MM, NHL | NCT04401020 | 1 | Sanofi |
| HPN217 | TriTAC | BCMA/HSA/CD3 | MM | NCT04184050 | 1 | Harpoon Therapeutics |
| ISB 2001 | TREAT | BCMA/CD38/CD3 | MM | NCT05862012 | 1 | Ichnos Sciences |
| CMG1A46 | TRIAD IgG-like 1:(1 + 1) | CD19/CD20/CD3 | NHL, ALL | NCT05348889 | 1 | Chimagen |
| JNJ-79635322 | Undisclosed | Undisclosed | MM | NCT05652335 | 1 | Janssen |
| JNJ-80948543 | IgG1-based Fab-scFv | CD79b/CD20/CD3 | NHL, CLL | NCT05424822 | 1 | Jansen |
| Emfizatamab (GNC-038) | NA | CD3/CD137/PD-L1/CD19 | NHL | NCT04606433 | 1 | Sichuan Baili Pharmaceutical |
| NCT05623982 | 1/2 | |||||
| MP0533 | DARPin | CD33/CD123/ CD70/CD3 | AML, MDS | NCT05673057 | 1/2 | Molecular Partners |
NA not available